Richard W Dixon

USPTO Granted Patents = 23 (Patent Applications = 15)

CIPO Patents = 3 (Patent Applications = 12)

EPO Patents = 5 (Patent Applications = 17)

Average Co-Inventor Count = 3.1

ph-index = 11

Forward Citations = 936(Granted Patents)

Location History:

Wheaton, MD (US) (1988 - 1989)
Gaithersburg, MD (US) (1993 - 1994)
Hewett, NJ (US) (2002)
North Grafton, MA (US) (2009 - 2013)
Jefferson, MA (US) (2008 - 2022)

Company Filing History:

9 out of 4,177

Abbott Laboratories Corporation

4. 6 out of 832,680

Other

patents

Years Active: 1988-2022

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11344621 - Interleukin-13 binding proteins (2022-05-31),

2. 10086076 - Interleukin-13 binding proteins (2018-10-02),

3. 9592293 - Interleukin-13 binding proteins (2017-03-14),

4. 8754107 - Aminopyrrolidines as chemokine receptor antagonists (2014-06-17),

5. 8629257 - IL-12/p40 binding proteins (2014-01-14),

6. 8604177 - Interleukin-13 binding proteins (2013-12-10),

7. 8475766 - Dual specificity antibodies and methods of making and using (2013-07-02),

8. 8258268 - Dual variable domain immunoglobulin and uses thereof (2012-09-04),

9. 8008481 - Indazole compounds (2011-08-30),

10. 7915388 - Interleukin-13 binding proteins (2011-03-29),

11. 7767207 - Antibodies that bind IL-18 and methods of inhibiting IL-18 activity (2010-08-03),

12. 7709468 - Imidazo based heterocycles (2010-05-04),

13. 7700739 - IL-12/p40 binding proteins (2010-04-20),

14. 7612181 - Dual variable domain immunoglobulin and uses thereof (2009-11-03),

15. 7491516 - Dual specificity antibodies and methods of making and using (2009-02-17),

Title: Richard W. Dixon: Innovator in Interleukin-13 Binding Proteins

Introduction

Richard W. Dixon, based in Jefferson, MA, has made significant contributions in the field of biotechnology with a total of 23 patents to his name. His work primarily focuses on the development of antibodies that target interleukin-13, a critical player in various inflammatory diseases.

Latest Patents

Among his latest innovations are the patents related to Interleukin-13 binding proteins. These inventions encompass antibodies that are chimeric, CDR grafted, and humanized. The preferred antibodies exhibit a high affinity for human interleukin-13 (hIL-13) and effectively neutralize its activity both in vitro and in vivo. These antibodies can exist as full-length antibodies or as antigen-binding portions, allowing flexibility in their application. The methods for creating and utilizing these antibodies are also elucidated in his patents, highlighting their potential for detecting hIL-13 and inhibiting its detrimental effects in humans suffering from related disorders.

Career Highlights

Throughout his career, Richard W. Dixon has worked for prominent companies such as Abbott Laboratories Corporation and AbbVie Inc. His experiences within these organizations have contributed substantially to his knowledge and expertise in the field of antibody research and development.

Collaborations

In his professional journey, Richard has collaborated with notable peers, including Chengbin Wu and Jonathan P. Belk. These collaborations have helped enhance the scope and impact of his research resulting in valuable advancements in therapeutic strategies.

Conclusion

Richard W. Dixon exemplifies innovation in biotechnology through his extensive patents and impactful collaborations. His work on interleukin-13 binding proteins presents promising avenues for medical interventions, showcasing the vital role inventors play in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.